8-K: SS Innovations Reports Strong Q4, Full-Year 2025 Revenue Growth

SS Innovations International, Inc. announced preliminary unaudited revenue and operating metrics for Q4 and full year 2025, showing significant growth in SSi Mantra surgical robotic system installations and revenue.

Summary

• Preliminary unaudited revenue for the fourth quarter of 2025 is expected to be approximately $15.0 million, an 85% increase from $8.1 million in Q4 2024.
• SSi Mantra installations for Q4 2025 are expected to be 37, up 68% from 22 installations in Q4 2024.
• Preliminary unaudited revenue for the full year 2025 is expected to be approximately $43.0 million, a 108% increase from $20.6 million in 2024.
• SSi Mantra installations for the full year 2025 are expected to be 103, up 119% from 47 installations in 2024.
• The SSi Mantra cumulative installed base totaled 168 as of December 31, 2025, representing a 158% increase from 65 as of December 31, 2024.
• The company has performed over 7,885 multi-specialty surgeries to date, including 400+ robotic cardiac surgeries and 120+ telesurgeries.
• Gross margin for 2025 is preliminarily estimated at 47.11%, an increase from 40.9% in 2024.
• The company anticipates U.S. FDA 510(k) premarket notification review and European Union CE marking certification for the SSi Mantra in the first half of 2026.

Sentiment

Score: 8

Explanation: The filing reports exceptionally strong preliminary revenue and installation growth, significant market expansion, and positive regulatory outlook, indicating robust operational performance and strategic execution despite continued net losses.

Positives

• Strong preliminary unaudited revenue growth of 85% for Q4 2025 and 108% for full year 2025, significantly outpacing market growth.
• Exceptional increase in SSi Mantra installations, with 68% growth in Q4 2025 and 119% for the full year 2025.
• The cumulative installed base grew 158% year-over-year to 168 systems, demonstrating rapid adoption.
• Anticipated FDA 510(k) clearance and EU CE marking certification in H1 2026 are major catalysts for expansion into key global markets.
• Successful global expansion with the SSi Mantra installed in 10 countries and over 7,885 multi-specialty surgeries performed.
• Pioneering telesurgery capabilities, including 120+ telesurgeries completed and the world's first intercontinental robotic cardiac telesurgery.
• Improving gross margins, estimated at 47.11% for 2025, up from 40.9% in 2024, indicating better cost management and scalability.
• Development of five new 5-millimeter surgical robotic instruments expands the system's versatility across multiple specialties, including pediatric and cardiac surgery.
• Strong insider ownership of 76.5% as of April 14, 2025, aligns management and shareholder interests.

Negatives

• The reported financial and operating results are preliminary, unaudited, and subject to change upon completion of final financial and accounting procedures.
• The company continues to report a net loss, with a preliminary estimated net loss of $(20,878,292) and diluted EPS of $(0.14) for the full year 2025.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied.
• Investors should exercise caution in relying on preliminary unaudited financial information, as it is subject to finalization of quarter-end financial and accounting procedures.
• Market data and estimates of potential market opportunities are based on assumptions and limitations, and may not accurately reflect actual market conditions.
• Access to robotic surgery remains limited globally due to high acquisition costs, unattractive economics for lower-volume hospitals, absence of trained personnel, and lack of versatility of existing systems.
• Regulatory timelines for FDA and EU CE Mark are estimates and dependent on the outcome of the review processes, which could be subject to delays or unfavorable decisions.

Future Outlook

The company anticipates U.S. Food and Drug Administration (FDA) 510(k) premarket notification review for the SSi Mantra to be completed in the first half of 2026, alongside obtaining European Union CE marking certification in the same period. It plans to expand its global presence, focusing on Ambulatory Surgical Centers (ASCs) and smaller hospitals in the U.S. after FDA approval, while leveraging its differentiated cardiac surgery capabilities. The company also expects to release its full fourth quarter and full year 2025 financial results in the latter part of February.

Management Comments

• "We expect to report strong fourth quarter revenue growth, driven by higher unit sales of our advanced, cost-effective SSi Mantra surgical robotic system in India and abroad."
• "We are committed to democratizing excellence in surgical care on a global scale, including in the United States and Europe."
• "We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra in the first half of 2026."
• "We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain in the first half of 2026."
• "We look forward to providing additional financial details when we release our fourth quarter financial results in the latter part of February."

Industry Context

The surgical robotics market is experiencing accelerated global adoption, with projections of 4x growth in surgeries conducted by robotic systems by 2030 and the market reaching $27.1 billion by 2030. SS Innovations positions itself to address the limited access to robotic surgery in underserved regions by offering an advanced, cost-effective system, contrasting with the high cost and limited versatility of existing systems like the da Vinci. The company's focus on India, a market with significant unmet needs and projected to reach almost $4 billion by 2031, aligns with these trends.

Comparison to Industry Standards

• The global surgical robotics market is projected to grow at a 14.7% CAGR, reaching $27.1 billion by 2030, indicating SS Innovations' revenue growth of 85% (Q4 2025) and 108% (FY 2025) is significantly outpacing the overall market.
• The SSi Mantra's cumulative installed base of 168 systems as of December 31, 2025, is growing rapidly, contrasting with the installed base of existing systems largely limited to the US, EU, and Japan, where 7 billion people have access to only 5% of installed systems.
• The company's focus on affordability and accessibility directly addresses the 'high cost of acquisition and implementation' and 'unattractive economics for hospitals with lower volumes' that characterize existing systems, including the >100 da Vinci robotic-assisted surgical systems installed across major private and government hospitals in India.
• SS Innovations is highlighted as the 'only company in the world actively advocating for robotic cardiac surgery,' targeting an untapped market potential in automated coronary artery bypass surgery, a niche not fully addressed by competitors.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue and installation growth, potential for increased market share, and anticipated regulatory approvals in key markets (US, EU). However, preliminary results are unaudited and net losses persist.
• Customers (Hospitals/Surgeons): Positive impact from the availability of a cost-effective, advanced surgical robotic system (SSi Mantra) that supports a wide range of procedures, including cardiac surgery, and offers telesurgery capabilities, potentially improving patient outcomes and resource utilization.
• Patients: Positive impact through increased access to affordable robotic surgery, reduced trauma, faster recovery times, less pain, and reduced risk of infection.
• Employees: Potential positive impact from company growth and expansion, possibly leading to increased opportunities and job security.

Next Steps

• Completion of U.S. FDA 510(k) premarket notification review in H1 2026.
• Obtaining European Union CE marking certification in H1 2026.
• Release of fourth quarter and full year 2025 financial results in the latter part of February.
• Continued global expansion, including strategic entry into Europe and the United States.
• Focus on Ambulatory Surgical Centers (ASCs) and smaller hospitals in the U.S. after FDA approval.
• Further development and innovation of the robotics platform, including new 5-millimeter instruments and AI/XR technologies.

Key Dates

Recommendation

The company demonstrates exceptional growth in revenue and system installations, significantly outpacing market averages. Anticipated FDA and CE Mark approvals in H1 2026 represent major catalysts for expansion into lucrative U.S. and European markets. The focus on affordability and advanced features like cardiac surgery and telesurgery positions SS Innovations to disrupt the surgical robotics industry, particularly in underserved regions. While preliminary and unaudited, the reported metrics indicate strong operational momentum and a clear path to future market penetration, making it a compelling investment despite current net losses.

Keywords

surgical robotics, SSi Mantra, medical technology, robot-assisted surgery, FDA approval, CE marking, India market, global expansion, Q4 2025 results, full year 2025 revenue, telesurgery, cardiac surgery, SS Innovations International, preliminary results